Save the Next Steve Jobs from Terminal Pancreatic Cancer Save the Next Steve Jobs from Terminal Pancreatic Cancer; Harness Australia’s Medical know-how and Israel’s Clinical-trial Advantage We now have a clearer understanding of the aggressive disease that killed Apple Founder, Steve Jobs. Neuroendocrine tumours usually develop in the digestive or respiratory tracts but can occur in other areas of the body. These tumours have the potential to become malignant without rapid diagnosis and early treatment, and the numbers of patients afflicted by the disease is growing steadily each year. Fifty percent of Neuroendocrine growths are diagnosed more than 5 years after the first symptoms appear, by which stage they have usually advanced to Grade 3 stage. The average survival rate for patients with aggressive Grade3 tumours is only 4-6 months. Researchers have now proposed a world-first randomised Phase 2 multi-centres trial that offers the potential of a more effective treatment and prolonged survival rate compared to standard chemotherapy. For further information regarding this significant research project, please contact our Development Directors.